GlobalData has released its new
Country report, PharmaPoint: Meningococcal Vaccines France Drug Forecast and
Market Analysis to 2022. Meningococcal disease is an acute infection caused by
the gram-negative bacterium Neisseria meningitidis. Its rapid onset and
severity of symptoms makes prompt and effective diagnosis and treatment nearly
impossible. For these reasons the meningococcal disease space is dominated by
vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra
and Novartis Menveo, account for the vast majority of global sales, with the US
adolescent market being the key target segment. GlobalData expects growth in
the meningococcal vaccines market to be primarily driven by the launch of
serotype B vaccines, which address a critical unmet need in the treatment
landscape. Vaccines that better protect infants and/or provide a longer
duration of immunity also have an opportunity to seize market share during
2012-2022.
To Read the Complete Report with TOC
Visit: http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-france-drug-forecast-and-market-analysis-to-2022
GlobalData does not expect relative
patient share to change within the MenC conjugate space because Nuron Biotechs
Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C all possess similar
clinical profiles and price points. The MenC conjugate patient share is largely
determined by prescriber preference in France and therefore is not expected to
change drastically during the forecast period. The French government has
expressed disappointment with the low coverage rates of its MenC immunization
program and is expected to renew efforts to expand vaccine use (Stahl et al.,
2013). In general, the sales potential in France is derived from the
immunization recommendations, which largely determine vaccine usage.
Scope
- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting France Meningococcal Vaccines market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in France
About Us
MarketResearchReports.Biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs,
our main offerings are syndicated research reports, custom research,
subscription access and consulting services. We serve all sizes and types of
companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment